FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use AuthorizationTORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical tri
Key Takeaways; Cannabis Sector Boston Beer announced the launch of a new line of cannabis-infused iced teas. Decibel reported rising revenue in Q1. Ayr Wellness reported positive revenue of $111.2 million, up 90% YoY. Key Takeaways; Psychedelic Sector Awakn filed PCT application for the treatment of behavioral addictions. The FDA gave Revive Therapeutics positive feedback […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.
WHO reports 650 probable cases of acute hepatitis of unknown aetiology in children from 33 countries Company received FDA orphan drug designation for Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation and Cannabidiol for autoimmune hepatitis Company intends to move its head office to the US to better support growing drug programs with Bucillamine, Cannabidiol, and Psilocybin TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the